In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche v. Biosite

This article was originally published in The Gray Sheet

Executive Summary

San Diego manufacturer Biosite believes patent infringement allegations filed Nov. 9 by Roche in Indianapolis federal court are without merit. The suit references two Roche U.S. patents covering a biosensing meter and a device used for separating plasma or serum from whole blood. Biosite markets the Triage line of drugs-of-abuse assays, cardiac marker test kits and B-type natriuretic peptide (BNP) point-of-care hormone diagnostic tests...

You may also be interested in...



Biosite sues Roche

San Diego firm files complaint in California district court alleging Roche Diagnostics is infringing on two patents related to methods for measuring cardiac troponin forms, according to a Nov. 30 release. The filing marks the second suit Biosite has brought against Roche in recent months. On Nov. 9, the firm brought patent infringement allegations in Indianapolis federal court regarding its biosensing meter and a device used for separating plasma or serum from whole blood (1"The Gray Sheet" Nov. 22, 2004, In Brief)...

Farxiga CKD Trial Stopped Early For Efficacy, Giving The SGLT2 Inhibitor An Edge

A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.

Approval Of Medtronic’s Renal Denervation System Delayed By COVID-19

Medtronic says that most of the clinical trials it is sponsoring are paused due to the pandemic, which means the completion of its PMA application for the Symplicity Spyral renal denervation system will be delayed.

UsernamePublicRestriction

Register

MT021220

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel